Radiation, Chemotherapy, and Immunotherapy for Rectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Rectal cancer confirmed by biopsy, located within 10 cm of the anal opening
- Cancer has not spread to distant organs
- No prior cancer treatment (radiation, chemotherapy, immunotherapy, or targeted therapy)
- Good overall health and ability to tolerate treatment (ECOG performance status 0–1)
- Blood counts and liver/kidney function within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This study tests a new treatment for locally advanced rectal cancer that combines an immunotherapy drug (PD-1 inhibitor) with a ketogenic diet and/or vitamin C. The goal is to see if this combination helps shrink tumors before surgery.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.